2012.06.04 Weekly Broadcast Email
The following updates were updates made to the CCCWFU CCOP Research Base website for the week of June 4, 2012.
New Study Opens: 97211
We are pleased to announce the opening of a new study, A Feasibility Study of Donepezil in Female Breast Cancer Survivors with Self-Reported Cognitive Dysfunction Following Chemotherapy.
The study protocol, consents and appendices can be found on the website: http://www.wakehealth.edu/cancer/researchBase/Protocols/97211/
(Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study)
New Instructions: For all patients assigned to the Quitline arm only: Immediately after faxing the Quit Line for Life Program Enrollment Form to the Quitline staff, email the request below to Mark Campbell, the Quitline contact person who will confirm your patients enrollment and ensure that your patient receives a phone call from the Quitline staff.
To Mark Campbell [Mark.Campbell@alere.com],
Study Participant # (insert PID only) has completed the Quit Line for Life Program Enrollment Form for Wake Forest Study 99211: “Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study.” This form was faxed to the Quitline staff on (insert date form was faxed).
If you did not receive this faxed participant enrollment form or if you have questions, please contact me as soon as possible.
(insert your name)
During the month of April, 45 patients were accrued to CCCWFU CCOP Research Base trials. Congratulations to CTSU for accruing the most patients. See the Research Base website spotlight section for further information.
There were no adverse events received during the month of May.
In preparation for the Annual Meeting in October, we would like to request that each site provide input as to the challenges that you face as well as the successful strategies that are utilized when screening and recruiting underserved populations to clinical trials. This information can be sent to Lisa Autry at firstname.lastname@example.org. We would like to receive this information by Wednesday June 13, 2012.